Higher levels of minimal residual disease in peripheral blood than bone marrow before 1st and 2nd relapse/regrowth in a patient with high‑risk neuroblastoma: A case report

• Published in: Oncology letters Vol. 26; no. 3; p. 369
• Main Authors: Inoue, Shotaro, Win, Kaung Htet Nay, Mon, Cho Yee, Fujikawa, Tomoko, Hyodo, Sayaka, Uemura, Suguru, Ishida, Toshiaki, Mori, Takeshi, Hasegawa, Daiichiro, Kosaka, Yoshiyuki, Nishimura, Akihiro, Nakatani, Naoko, Nino, Nanako, Tamura, Akihiro, Yamamoto, Nobuyuki, Nozu, Kandai, Nishimura, Noriyuki
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.09.2023; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Bone marrow; Cancer; Cancer therapies; Case Report; Case reports; Chemotherapy; Immunotherapy; Laboratories; Metastasis; Neuroblastoma; Oncology; Patients; Prognosis; Remission (Medicine); Vincristine; Canada; Japan; Germany; neuroblastoma; minimal residual disease; peripheral blood; relapse/regrowth; neuroblastoma-associated mRNAs; bone marrow

More than half of patients with high-risk neuroblastoma (HR-NB) experience relapse/regrowth due to the activation of chemoresistant minimal residual disease (MRD). MRD in patients with HR-NB can be evaluated by quantitating neuroblastoma-associated mRNAs (NB-mRNAs) in bone marrow (BM) and peripheral...